PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11334998-3	2001	In addition to this, TH induction and DA plus DOPAC production was observed in foetal human and rat cerebral cortex by using glial-cell derived neurotrophic factor (GDNF) in place of BDNF.	3,4-Dihydroxyphenylacetic Acid	46-51	glial cell derived neurotrophic factor	Rattus norvegicus	125-163	
11277973-9	2001	GDNF pretreatment also protected against 6-hydroxydopamine-induced reductions in striatal DOPAC levels in all age groups.	3,4-Dihydroxyphenylacetic Acid	90-95	glial cell derived neurotrophic factor	Rattus norvegicus	0-4	
11334998-3	2001	In addition to this, TH induction and DA plus DOPAC production was observed in foetal human and rat cerebral cortex by using glial-cell derived neurotrophic factor (GDNF) in place of BDNF.	3,4-Dihydroxyphenylacetic Acid	46-51	glial cell derived neurotrophic factor	Rattus norvegicus	165-169	
9449424-7	1997	Consistent with the behavioral changes, levels of DA and the metabolite dihydroxyphenylacetic acid (DOPAC) were elevated (by 98% and 65%, respectively) in the SN, but not the striatum of Ad-GDNF-injected rats.	3,4-Dihydroxyphenylacetic Acid	100-105	glial cell derived neurotrophic factor	Rattus norvegicus	190-194	
11085315-9	2000	Basal levels of DOPAC and HVA were also elevated on the GDNF-treated side of the brain.	3,4-Dihydroxyphenylacetic Acid	16-21	glial cell derived neurotrophic factor	Rattus norvegicus	56-60	
9753113-8	1998	Post-mortem neurochemical analysis at 13 weeks after surgery found that GDNF significantly inhibited 6-OHDA-induced loss of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the ipsilateral striatum.	3,4-Dihydroxyphenylacetic Acid	134-164	glial cell derived neurotrophic factor	Rattus norvegicus	72-76	
11085910-4	2000	In the 10 microgram GDNF-treated rats, there was a significant increase in the peak DA output in response to the second versus first K(+) infusion, a significant increase in both basal and overall K(+)-evoked DOPAC responses, and significantly increased striatal DA and DOPAC contents compared with vehicle- or 1 microgram GDNF-treated rats.	3,4-Dihydroxyphenylacetic Acid	209-214	glial cell derived neurotrophic factor	Rattus norvegicus	20-24	
11085910-4	2000	In the 10 microgram GDNF-treated rats, there was a significant increase in the peak DA output in response to the second versus first K(+) infusion, a significant increase in both basal and overall K(+)-evoked DOPAC responses, and significantly increased striatal DA and DOPAC contents compared with vehicle- or 1 microgram GDNF-treated rats.	3,4-Dihydroxyphenylacetic Acid	270-275	glial cell derived neurotrophic factor	Rattus norvegicus	20-24	
9449424-9	1997	These results suggest that virally delivered GDNF promotes the recovery of nigral dopaminergic tone (i.e.: increased DA and DOPAC levels) and improves behavioral performance (i.e.: decreased rotations, increased locomotion) in rodents with extensive nigrostriatal dopaminergic denervation.	3,4-Dihydroxyphenylacetic Acid	124-129	glial cell derived neurotrophic factor	Rattus norvegicus	45-49	
9262339-3	1997	In vivo microdialysis studies showed that basal extracellular levels of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, were significantly increased in the striatum of the GDNF-treated rats.	3,4-Dihydroxyphenylacetic Acid	107-137	glial cell derived neurotrophic factor	Rattus norvegicus	213-217	
9042532-8	1997	GDNF significantly increased striatal (approximately 28%) and nigral (up to 40%) dopamine, as well as regulated the dopamine metabolites homovanillic acid and dihydroxyphenylacetic acid.	3,4-Dihydroxyphenylacetic Acid	159-185	glial cell derived neurotrophic factor	Rattus norvegicus	0-4